[Changes of glucose in the brains of monkeys with MPTP induced Parkinson's disease]

Related Experiment Video

Updated: May 9, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Peng Li1, Zhu-Jun Zhang, Yang Li

  • 1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.

Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition
|August 1, 2013
PubMed
Abstract

Insights

MPTP-induced Parkinson

Area of Science:

  • Neuroscience
  • Primate models
  • Neurodegenerative diseases

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms.
  • MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to create animal models of PD.
  • Understanding the brain-wide metabolic changes in PD models is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the metabolic and behavioral alterations in monkeys following MPTP administration.
  • To establish a reliable MPTP-induced Parkinson's disease model in non-human primates.
  • To explore the extent of glucose metabolism changes in the brain beyond the basal ganglia.

Main Methods:

  • Four healthy monkeys received continuous peripheral intravenous injections of MPTP.
  • Behavioral assessments were conducted using a standardized Parkinson's disease scale for monkeys.
  • 18FDG-PET-CT scans were performed pre- and post-MPTP injection to evaluate brain glucose metabolism.

Main Results:

  • Successful establishment of the MPTP-induced Parkinson's disease model in all monkeys, exhibiting bradykinesia, rigidity, and hypokinesia.
  • Observed behavioral changes included apathy and reduced aggression, with Parkinson's scale scores exceeding 20.
  • 18FDG-PET-CT revealed significant glucose hypometabolism within and outside the basal ganglia following MPTP exposure.
  • Motor symptoms showed improvement after treatment with Sinemet.

Conclusions:

  • MPTP-induced Parkinson's disease in monkeys results in widespread brain metabolic changes, not confined to the basal ganglia.
  • These extra-basal ganglia metabolic alterations may underlie the non-motor symptoms observed in Parkinson's disease.
  • The established primate model provides valuable insights into PD pathophysiology and potential therapeutic targets.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...